A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma

Shu Yein Ho, Po Hong Liu, Chia Yang Hsu, Yi Hsiang Huang, Jia I. Liao, Chien Wei Su, Ming Chih Hou, Teh Ia Huo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The prognosis of hepatocellular carcinoma (HCC) varies widely due to variable tumor extent and liver reserve. We aimed to develop and validate a new prognostic model based on tumor burden score (TBS) and albumin–bilirubin (ALBI) grade for HCC. We prospectively identified 3794 HCC patients who were randomized into derivation and validation groups. Survival predictors were evaluated by a multivariate Cox model. The TBS–ALBI system allocated two points for high TBS and ALBI grade 3, and one point each for the presence of ascites, serum α-fetoprotein ≥ 400 ng/mL, vascular invasion or distant metastasis, performance status 2–4, medium TBS, and ALBI grade 2, with a maximal score of 8 points. Significant survival differences were found across different TBS–ALBI score groups in the validation cohort (all p < 0.001). The TBS–ALBI system had the lowest corrected Akaike information criterion (AICc) and the highest homogeneity compared with other proposed staging models. The discriminative ability of the TBS–ALBI system was consistently stable across different viral etiologies, cancer stages, and treatment strategies. Conclusions: This new TBS–ALBI system is a feasible and robust prognostic system in comparison with other systems; it is a user-friendly tool for long-term outcome assessment independent of treatment modality and cancer stage in HCC.

Original languageEnglish
Article number649
JournalCancers
Volume14
Issue number3
DOIs
StatePublished - 1 Feb 2022

Keywords

  • Albumin–bilirubin grade
  • Hepatocellular carcinoma
  • Prognosis
  • Tumor burden score

Fingerprint

Dive into the research topics of 'A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this